Skip to content
value.today

Spring Bank Pharmaceuticals, Inc.

Total raised
$37 M
2 rounds on record
Latest round
$15 M
Nov 2016
First round on record
Dec 2014
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Spring Bank Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2016$15 MNo. 2$10 to $50 million

Spring Bank Pharmaceuticals, Inc.: Raise no. 2, Nov 2016

Investors in this round

24 investors had bought by the notice of Nov 23, 2016: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$900,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Freve · Executive Officer
  • Martin Driscoll · Executive Officer, Director
  • Nezam Afdhal · Executive Officer
  • David Kris Arkowitz · Director
  • Jonathan Kris Bates · Director
  • Kurt M. Eichler · Director
  • R.P. Kris Iyer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • William Blair & Company, L.L.C. (CRD 1252) · Chicago, IllinoisSold in all US states

Signed by Jonathan Freve, Chief Financial Officer. Newest notice filed Nov 23, 2016. Read the notice at the SEC.

equity, optionsSEC
Dec 2014$22 MNo. 1$10 to $50 million

Spring Bank Pharmaceuticals, Inc.: Raise no. 1, Dec 2014

Investors in this round

72 investors had bought by the notice of Feb 27, 2015: 72 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,589,317
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas John Jensen · Executive Officer, Director
  • Radhakrishnan Parameswaran Iyer · Executive Officer, Director
  • David Ellsworth Arkowitz · Director
  • Guy Parameswaran Macdonald · Director
  • Jonathan Ellsworth Bates · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Gilford Securities (CRD 8076) · New York, New YorkSold in all US states

Signed by Douglas J. Jensen, Chief Executive Officer. Newest notice filed Feb 27, 2015 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Spring Bank Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2016).

    SEC Form D · Nov 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Spring Bank Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Spring Bank Pharmaceuticals, Inc.
NameRoleNamed in
Jonathan FreveExecutive officerNov 2016
Martin DriscollExecutive officerNov 2016
Nezam AfdhalExecutive officerNov 2016
Douglas John JensenExecutive officerFeb 2015
Radhakrishnan Parameswaran IyerExecutive officerFeb 2015
David Kris ArkowitzDirectorNov 2016
Jonathan Kris BatesDirectorNov 2016
Kurt M. EichlerDirectorNov 2016
Martin DriscollDirectorNov 2016
R.P. Kris IyerDirectorNov 2016
David Ellsworth ArkowitzDirectorFeb 2015
Douglas John JensenDirectorFeb 2015
Guy Parameswaran MacdonaldDirectorFeb 2015
Jonathan Ellsworth BatesDirectorFeb 2015
Radhakrishnan Parameswaran IyerDirectorFeb 2015